Pear Therapeutics, Inc. announced results from a retrospective analysis to evaluate the impact of Somryst® on healthcare resource use (HCRU).1 Results found that use of Somryst, the only FDA-authorized PDT for the treatment of chronic insomnia, was associated with significant and durable real-world HCRU reductions and cost savings compared to sleep medicines alone.2 These findings were presented as a poster at ISPOR Europe 2022 held November 6-9, 2022, in Vienna, Austria and virtually, and were previously presented at AMCP Nexus 2022 in October and the 2022 NEI Congress earlier this month. The analysis evaluated real-world data of 248 adult patients with chronic insomnia treated with Somryst over 24-months compared to matched controls treated with chronic insomnia medications and found: Reductions in health-related services including: Emergency department services (59%; IRR =0.41; P<0.001). Hospitalizations (55%; IRR =0.45; P=0.001).

Hospital outpatient visits (36%; IRR =0.64; P<0.001). Ambulatory surgical center services (23%; IRR =0.77). Office visits (7%; IRR =0.93).

An estimated $8,202 reduction in per-patient costs were observed compared to controls treated with chronic insomnia medications.